

DAFTAR PUSTAKA

1. Suwitra K. Penyakit ginjal kronik. Dalam Buku Ajar Ilmu Penyakit Dalam. Ed keenam Jilid II. Editor oleh Setiati S, Alwi I, Sudoyo AW, Simadibrata KM, Setiyohadi B, Syam AF. Jakarta: Interna publishing. 2014: 2159–65
2. KDIGO. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2012
3. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, *et al.* Global prevalence of chronic kidney disease-a systematic review and meta-analysis. *PLOS One.* 2016: 1–18
4. Provenzano M, Coppolino G, De Nicola L, Serra R, Garofalo C, Andreucci M, *et al.* Unraveling cardiovascular risk in renal patients: a new take on old tale. *Front Cell Dev Biol.* 2019;7:314
5. Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2021
6. Grams ME, McDonald SP. Epidemiology of chronic kidney disease and dialysis. In: Feehally J *et al.* *Comprehensive Clinical Nephrology* 6th Edition. Edinburgh: Elsevier. 2019:903–12
7. InfoDATIN. Situasi Penyakit Ginjal Kronis. Pusat Data dan Informasi Kementerian Kesehatan RI. 2017
8. De Vecchi AF, Dratwa M, Wiedemann ME. Healthcare system and end-stage renal disease (ESRD) therapies-an international review: costs and reimbursement/funding of ESRD therapies. *Nephrol Dial Transplant.* 1999;14 Suppl 6:31–41
9. Lopez-Hernandez FJ, Lopez-Novoa JM. Role of TGF- β in chronic kidney disease: an integration of tubular, glomerular and vascular effects. *Cell Tissue Res.* 2012;347: 141–54
10. Lena B, Iris F, Paul VJ, Solange M, Pierre-Yves M, Sophie DS. Diagnosis and assessment of renal fibrosis: the state of the art. *Swiss Med Wkly.* 2017;147:w14442
11. Breit M, Weinberger KM. Metabolic biomarkers for chronic kidney disease. *Archives of Biochemistry and Biophysics.* 2015:122

12. Wong MG, Pollock CA. Biomarkers in kidney fibrosis: are they useful?. *Kidney International Supplements*. 2014; 4:79–83
13. Mansour SG, Puthumana J, Coca SG, Gentry M, Parikh CR. Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review. *BMC Nephrology*. 2017; 18:72
14. Border WA, Noble NA. Transforming growth factor- β in tissue fibrosis. *The New England Journal of Medicine*. 1994;331: 1286–92
15. Schnaper HW, Jandeska S, Runyan CE, Hubchak SC, Basu RJ, Curley JF. TGF-beta signal transduction in chronic kidney disease. *Front Biosci (Landmark Ed)*. 2009;14: 2448–65
16. Schiffer M, Bitzer M, Roberts IS. Apoptosis in podocytes induced by TGF-beta and smad7. *The Journal of Clinical Investigation*. 2001; 108(6): 807–16
17. Bottinger EP, Bitzer M. TGF- β signaling in renal disease. *Journal of American Society of Nephrology*. 2002; 139(10): 2600–10
18. Cheng J and Grande JP. Transforming growth factor- β signal transduction and progressive renal disease. *Experimental Biology and Medicine*. 2002; 227(11): 943–56
19. Nguyen VT, Duc NK, Hoang TM, Dam LTP, Huynh TQ. Evaluating the serum transforming growth factor-beta 1 level in chronic kidney disease caused by glomerulonephritis. *Nephro-Urol Mon*. 2021; 13(2): e113161
20. Goumenos DS, Tsakas S, El Nahas AM, Alexandri S, Oldrovd S. Transforming growth factor- β 1 in the kidney and urine of patients with glomerular disease and proteinuria. *Nephrol Dial Transplant*. 2009;111(2): 127–32
21. Arata S, Ohmi A, Mizukoshi F, Baba K, Setoguchi A. Urinary transforming growth factor-beta1 in feline chronic renal failure. *The Journal of Veterinary Medical Science*. 2005;67:1253–55
22. Habenicht LM, Webb TL, Clauss LA, Dow SW, Quimby JM. Urinary cytokine levels in apparently healthy cats and cats with chronic kidney disease. *Journal of Feline Medicine and Surgery*. 2013;15:99–104

23. Tsakas S, Goumenos DS. Accurate measurement and clinical significance of urinary transforming growth factor-beta1. *Am J Nephrol.* 2006;26:186–93
24. Ekrikpo UE, Kengne AP, Bello AK, Effa EE, Noubiap JJ, Salako BL, et al. Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis. *PLoS One.* 2018;13(4) : e0195443
25. Hemmelgarn B, Manns B, Lloyd A. Relation between kidney function, proteinuria, and adverse outcomes. *JAMA.* 2010; 303: 423–29
26. Chakrabarti S, Syme HM, Brown A, Elliott J. Hystomorphometry of feline chronic kidney disease and correlation with markers of renal dysfunction. *Veterinary Pathology.* 2012;50(1):147–55
27. Huang L, Yuezhong L, Chao W, Haitao T. The urine albumin-to-creatinine ratio is reliable indicator for evaluating complication of chronic kidney disease and progression in IgA nephropathy in China. *Clinics.* 2016;71(5):243–50
28. Eunhee Ji, Kim YS. Prevalence of chronic kidney disease defined by using CKD-EPI equation and albumin-to-creatinin ratio in the Korean adult population. *Korean J Intern Med.* 2016;31(6):1120–30
29. [Sumida K](#), [Nadkarni GN](#), [Grams ME](#), [Sang Y](#), [Ballew SH](#), [Coresh J et al.](#) Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis : An individual participant-based meta-analysis. *Ann Intern Med.* 2020 Sep 15;173(6):492–93
30. Ghayur A, Margetts PJ. Transforming growth factor-beta and the glomerular filtration barrier. *Kidney Res Clin Pract.* 2013:3–10
31. Bargman JM, Skorecki K. Chronic kidney disease. In Harrison,s principles of internal medicine.. Ed 19 . Editors by Kasper DL, Hauster SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J.USA : Mc Graw-Hill.2015:1811–14
32. El Nahas AM, Bello AK. Chronic kidney disease : the global challenge. *Lancet.* 2005;365(9456):331–40

33. Silva AAS, Prestes TRR, Lauar AO, Finotti BB, e Silva ACS. Renin angiotensin system and cytokines in chronic kidney disease : clinical and experimental evidence. Bentham Science Publishers. 2017;24:799–808
34. [Chang](#) AS, [Hathaway](#) CK, [Smithies](#) O, [Kakoki](#) M. Transforming growth factor- β 1 and diabetic nephropathy. [Am J Physiol Renal Physiol](#). 2016;15; 310(8): F689–96
35. Roberts AB, Sporn MB. Physiological action and clinical application of transforming growth factor- β . *Growth Factors*. 1993;8:1–9
36. Lawrence AD, Transforming growth factor- β : an overview. *Kidney Int*. 1995;47(49):19–23
37. Gleizes PE, Munger JS, Nunes I, Harpel JG, Mazzier R, Noguera I, Rifkin DB. TGF- β latency: biological significance and mechanisms of activation. *Stem Cells*. 1997;15:190–7
38. Shi M, Zhu J, Wang R, Chen X, Mi L, Waltz T, Springer TA. Latent TGF- β structure and activation. *Springer*. 2011;474:343–51
39. Attisano L, Wrana JL. Signal transduction by TGF- β superfamily. *Science*. 2002;296:746–56
40. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. *Front Biosci*. 2002Apr 1;7:d793–807
41. Leivonen SK, Kahari VM. Transforming growth factor- β signaling in cancer invasion and metastasis. *Int. J Cancer*. 2007;121:2119–24
42. Tominaga K, Suzuki HI. TGF- β signaling in cellular senescence and aging-related pathology. *Int J Mol Sci*. 2019;20(20):5002
43. Gu YY, Liu XS, Huang XR, Yu XQ, Lan HY. Diverse role of TGF- β 1 in kidney disease. *Front. Cell Dev. Biol*. 2020;8:123
44. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF- β : the master regulator of fibrosis. *Nat Review Nephrol*. 2016;12:325–38
45. Haramaki R, Tamaki K, Fujisawa M. Steroid therapy and urinary transforming growth factor- β 1 in IgA nephropathy. *Am J Kidney Dis*. 2001;38:1191–98
46. [Zhang](#) A, [Huang](#) S. Progress in pathogenesis of proteinuria. *Int J Nephrol*. 2012;3:14251

47. Benigni A, perico N, Remuzzi G. Pathophysiology of Disease Progression in Proteinuric and Nonproteinuric Kidney Disease. In: Feehally j et al. Comprehensive Clinical Nephrology 6th Edition. Edinburgh: Elsevier. 2019. p913–34
48. Newman DJ, Pugia MJ, Lott JA, Wallace JF, Hiar AM. Urinary protein and albumin excretion corrected by creatinine and specific gravity. Clin Chim Acta. 2000;294:139–55
49. Guh JY. Proteinuria versus albuminuria in chronic kidney disease. Asian Pasific Society of Nephrology. 2010;15:53–6
50. Tai M, Lam K, Lee W, Hsu K, Wu C, Cheng B, et al. Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease. Journal of Clinical Laboratory Analysis. 2012;26: 82–9
51. Gosling J, Czyz P, Nightingale M, Manji. Microalbuminuria in the intensive care unit: clinical correlates and association with outcomes in 431 patients. Crit Care Med. 2006; 34:2158–66.
52. Dwyer B, Gorman M, Carroll I, Druzin M. Urinalysis vs urine protein creatinine ratio to predict significant proteinuria in pregnancy. J Perinatol. 2008; 28(7):461–70
53. Witte E, Lambers H, De Zeeuw D. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol. 2009; 20: 436–43
54. Dubey A, Sahoo J, Vairappan B, Haridasan S, Parameswaran S, Priyamvada P. Correction of metabolic acidosis improve muscle mass and renal fuction in CKD stage 3 and 4: A Randomized control trial. Nephrol Dial Transplant. 2018; 1–9
55. Trivedi H, Vanikar A, Patel H, Kanodia K, Kute V, Nigam L, et al. High prevalence of chronic kidney disease in a semi urban population of Western India. Clin Kidney. 2016; 9(3) :438–43
56. Wen CP, Cheng TYD, Tsai MK, Chang Yc, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease a prospective cohort study based on 462293 adult in Taiwan. Lancet. 2008;371:2173–82

57. Ariani G, Harun H, Priyono D. Korelasi antara endotelin-1 serum dengan rasio albumin kreatinin urin pada pasien penyakit ginjal kronik[Tesis]. Padang: Fakultas Kedokteran Universitas Andalas;2021
58. Ihsani A, Harun H, Priyono D. Korelasi antara kadar asam urat serum dengan endotelial nitric oxide synthase (eNOS) pada pasien penyakit ginjal kronik [Tesis]. Padang: Fakultas Kedokteran Universitas Andalas;2021
59. Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, *et al.* Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team: Trends in prevalence of chronic kidney disease in the United States. *Ann Intern Med.* 2016; 165:473–81
60. Habib K, Mallhi K, Sarriff A, Khan A, Tanveer N. Prevalence of chronic kidney disease in Asia: A systematic review of population-based studies. *Journal of the College of Physicians and Surgeons Pakistan* 2018 ;12: 960–66
61. Ricardo AC, Yang W, Sha D, Appel LJ, Chen J, Krousel-Wood M, *et al.* Sex-related disparities in CKD progression. *J Am Soc Nephrol.* 2019;30:137–46
62. Neugarten J, Golestaneh L. Gender and the prevalence and progression of renal disease. *Adv Chronic Kidney D.* 2013;20(5):390–5.
63. Silbiger S, Neugarten J. Gender and human chronic renal disease. *Gend Med.* 2008;5:S3–10.
64. Goldberg I, Krause I. The role of gender in chronic kidney disease. *EMJ.* 2016;1(2):58–64.
65. Kim MJ, Lim NK, Park HY. Relationship between prehypertension and chronic kidney disease in middle-aged people in Korea: the Korean genome and epidemiology study. *BMC Public Health.* 2012;12:960
66. Kalaitzidis RG, Bakris GL. Prehypertension: is it relevant for nephrologists?. *Kidney International.* 2010;77: 194–200
67. [Crews](#) DC, Plantinga LC, Miller III ER, Saran R, Hedgeman E, Saydah SH *et al.* Prevalence of Chronic Kidney Disease in Persons With Undiagnosed or Prehypertension in the United States. *Hypertension.* 2010;55:1102–09

68. Sauriasari R, Pratiwi MY. Urinary TGF- β 1 not independently associated with renal function in diabetes mellitus. *Diabetes, Metabolic Syndrome and Obesity: Target and Therapy*. 2018;11:597–602
69. Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. *Drugs*. 2020;80:1381
70. Oh T, Choi H, Kim C, Bae E, Ma S, Sung S, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. *Sci Rep*. 2019;9(1): 1 – 9.
71. Kalani L, Raphael, Sarah G, Thomas H, Hostetter, Tom G, Srinivasan B. Association between Urine Ammonium and Urine TGF- β 1 in CKD. *CJASN*. 2018, 13 (2) 223–30
72. Lawson JS, Syme HM, Wheeler-Jones CPD, Elliot J. Urinary active transforming growth factor- β in feline chronic kidney disease. *Vet J*. 2016;214:1–6
73. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. *Diabetes Care*. 2002;25(6):1072–77
74. De Muro P, Faedda R, Fresu P, Masala A, Cigni A, Concas G, et al. Urinary transforming growth factor-1 in various types of nephropathy. *Pharmacological Research*. 2004;49: 293–98
75. Ellis D, Forrest KYZ, Erbey J, Orchard TJ. Urinary measurement of transforming growth factor- β and type IV collagen as new marker of renal injury: application in diabetic nephropathy. *Clinical Chemistry*. 1998;44(5):950–56.
76. Shaker YM, Soliman HA, Ezzat E, et al. Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic nephropathy patients. *Beni-Suef Univ J Basic Appl Sci*. Elsevier Ltd. 2014;3(1):16–23.
77. Ernesto L, Schiffrin, Mark L, Lipman, Johannes. Chronic kidney disease. Effect on the cardiovascular system. *AHA Journals*. 2007;116: 85–97

78. Gilbert RE, Akdeniz A, Allen TJ, Jerums G: Urinary transforming growth factor- β in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology. *Nephrol Dial Transplant* 2001;16:2442–43
79. Ha SW, Kima HJ, Bae JS, Jeong GH, Chung SC, Kim JK, et al. Elevation of urinary ig-h3, transforming growth factor--induced protein in patients with type 2 diabetes and nephropathy. *Diabetes Research and Clinical Practice*. 2004;65: 167–73
80. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, *et al.* Expression of transforming growth factor- β isoform in human glomerular disease.
81. Das R, Xu S, Quan X, Nguyen TT, Kong ID, Chung CH *et al.* Upregulation of mitochondrial Nox4 mediates TGF- β induced apoptosis in cultured mouse podocytes. *Renal Physiol*. 2014;306:155–67
82. Weng Z, Yu L, Wang L, Hao Z, Zhang Y. The relationship between transforming growth factor β gene expression and steroid therapy in children nephritic syndrome. Presented in the 9th Asian Congress of Pediatric Nephrology, Oct 28-30 2005.
83. Honkanen E, Teppo AM, Tornroth T, Groop PH, Riska CG. Urinary transforming growth factor- β 1 in membranous glomerulonephritis. *Nephrol Dial Transplant*. 1997;12:2562–68
84. Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. *World J Nephrol*. 2015;4(1):57–73
85. Rivarola EW, Moyses-Neto M, Dantas M, da-Silva CG, Volpini R, Coimbra TM. Transforming growth factor beta activity in urine of patients with type 2 diabetes and diabetic nephropathy. *Braz J Med Biol Res*. 1999;32(12):1525–28
86. Hellmich B, Schellner M, Schatz H, Pfeiffer A. Activation of transforming growth factor-beta1 in diabetic kidney disease. *Metabolism*. 2000;49(3):353–59

87. El Mesallamy HO, Ahmed HH, Bassyouni AA, Ahmed AS, Ahmed ME.
Clinical significance of inflammatory and fibrogenic cytokines in diabetic
nephropathy. *Clin Biochem.* 2012;45(9):646–50

